Dr. David VanderWeele
Claim this profileNorthwestern University
Area of expertise
Prostate Cancer
David VanderWeele has run 8 trials for Prostate Cancer. Some of their research focus areas include:
Bladder Cancer
David VanderWeele has run 3 trials for Bladder Cancer. Some of their research focus areas include:
Affiliated Hospitals
Northwestern University
Northwestern Medicine Lake Forest Hospital
Clinical Trials David VanderWeele is currently running
FDG-PET-Guided Radiation Therapy
for Prostate Cancer
This phase II trial compares the effect of FDG-positron emission tomography (PET)-guided metastasis directed radiation therapy (MDRT) in combination with standard treatments to standard treatments alone in treating patients with prostate cancer that is sensitive to androgen-deprivation therapy (ADT) and has spread from where it first started (primary site) to other places in the body (metastatic). Prostate cancer is the second leading cause of cancer death among men in the United States, despite the approval of several life-prolonging treatments by the Food and Drug Administration. However, over the past 10 years, there have been significant improvements in prolonging the lives of those with metastatic hormone sensitive prostate cancer, specifically by adding treatments to standard therapy, such as ADT. More recently, trials have demonstrated a benefit of using radiotherapy (high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors) to delay the progression of cancer and prolong life for patients with metastatic disease. Imaging scans with FDG-PET may be able to identify cancer sites that remain active despite standard treatment. Giving MDRT plus standard treatment to patients with FDG-PET-identified cancer sites may work better than standard treatment alone in treating metastatic hormone sensitive prostate cancer.
Recruiting
1 award
Phase 2
Blood Test and Immunotherapy
for Bladder Cancer
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer from coming back, can be identified by a blood test. Many types of tumors tend to lose cells or release different types of cellular products including their DNA which is referred to as circulating tumor DNA (ctDNA) into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for disease progression or relapse. In this study, a blood test is used to measure ctDNA and see if there is still cancer somewhere in the body after surgery and if giving a treatment will help eliminate the cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and relatlimab, can help the body's immune system to attack the cancer, and can interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine if ctDNA measurement in blood can better identify patients that need additional treatment, if treatment with nivolumab prolongs patients' life and whether the additional immunotherapy treatment with relatlimab extends time without disease progression or prolongs life of urothelial cancer patients who have undergone surgical removal of their bladder, kidney, ureter or urethra.
Recruiting
1 award
Phase 2 & 3
10 criteria
More about David VanderWeele
Clinical Trial Related
7 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments David VanderWeele has experience with
- Carboplatin
- Prednisone
- Nivolumab
- Cabazitaxel
- Abiraterone Acetate
- Enzalutamide
Breakdown of trials David VanderWeele has run
Prostate Cancer
Bladder Cancer
- Durvalumab + Chemo/Radiation for Bladder Cancer
- Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)
- Blood Test and Immunotherapy for Bladder Cancer
Renal Cell Carcinoma
Kidney Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David VanderWeele specialize in?
David VanderWeele focuses on Prostate Cancer and Bladder Cancer. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is David VanderWeele currently recruiting for clinical trials?
Yes, David VanderWeele is currently recruiting for 2 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that David VanderWeele has studied deeply?
Yes, David VanderWeele has studied treatments such as Carboplatin, Prednisone, Nivolumab.
What is the best way to schedule an appointment with David VanderWeele?
Apply for one of the trials that David VanderWeele is conducting.
What is the office address of David VanderWeele?
The office of David VanderWeele is located at: Northwestern University, Chicago, Illinois 60611 United States. This is the address for their practice at the Northwestern University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.